The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives
Open accessAbstract
The inflammasome is a molecular platform formed by activation of an innate immune pattern recognition receptor seed, such as NLRP3. Once activated, NLRP3 recruits the adapter ASC (apoptosis-related speck-like protein containing a caspase recruitment domain), which in turn recruits procaspase-1. Procaspase-1 autocatalyzes its cleavage and activation, resulting in maturation of the precursor forms of interleukin (IL)-1β and IL-18 into active proinflammatory cytokines and initiation of pyroptotic cell death. The NLRP3 inflammasome has been implicated in the pathogenesis of a wide variety of diseases, including genetically inherited autoinflammatory conditions as well as chronic diseases in which NLRP3 is abnormally activated. The NLRP3 inflammasome has been linked to diseases such as Alzheimer's disease, atherosclerosis, metabolic syndrome, and age-related macular degeneration. In this review, we describe the NLRP3 inflammasome complex and its activation in disease, and detail the current therapies that modulate either the NLRP3 inflammasome complex itself or the two cytokines it is responsible for activating, ie, IL-1β and IL-18.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066 · cited 1×
“Introduction The inflammasome was first described in 2002 by Tschopp as a large molecular platform that triggers the activation of inflammatory caspases and processing of prointerleukin-1β.(1) It is now known that these inflammasomes act as signaling platforms that can respond to a plethora of microbial products, as w…”
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
Inflamm‐aging: An Evolutionary Perspective on Immunosenescence
FRANCESCHI, C., BONAFÈ, M., VALENSIN, S., OLIVIERI, F., DE LUCA, M., OTTAVIANI, E., & DE BENEDICTIS, G. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06651.x · Cited by 5,358
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026 · cited 1×
“36 IL-1 β is known to play a causative role in many of the NLRP3 inflammasome-related diseases.”
Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466 · cited 1×
“Therapeutic use of IL-1β IL-1 is a multifunctional cytokine.(79) Alongside its well known proinflammatory and fever-inducing properties, there is also an established protective effect of IL-1β in mice after irradiation or treatment with cytotoxic drugs, most likely due to the ability of IL-1β to induce levels of colon…”
Cited by
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
Swanson, K. V., Deng, M., & Ting, J. P.-Y. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0165-0 · Cited by 4,884
Molecular mechanisms regulating NLRP3 inflammasome activation
Jo, E.-K., Kim, J. K., Shin, D.-M., & Sasakawa, C. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.95 · Cited by 1,378
NLRP3 inflammasome and its inhibitors: a review
Shao, B.-Z., Xu, Z.-Q., Han, B.-Z., Su, D.-F., & Liu, C. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00262 · Cited by 836
“Coll et al. (2015) further showed that MCC950 acts specifically on the NLRP3 inflammasome: it does not inhibit the activation of NLRP1, AIM2, or NLRC4 inflammasomes.”
BackgroundInfluentialPharmacological Inhibitors of the NLRP3 Inflammasome
Zahid, A., Li, B., Kombe, A. J. K., Jin, T., & Tao, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02538 · Cited by 671
Innate immunity in diabetic kidney disease
Tang, S. C. W., & Yiu, W. H. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0234-4 · Cited by 596
Minutoli, L., Puzzolo, D., Rinaldi, M., Irrera, N., Marini, H., Arcoraci, V., Bitto, A., Crea, G., Pisani, A., Squadrito, F., et al. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/2183026 · Cited by 505
Jurcau, A., & Simion, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010014 · Cited by 500
The Impact of Western Diet and Nutrients on the Microbiota and Immune Response at Mucosal Interfaces
Statovci, D., Aguilera, M., MacSharry, J., & Melgar, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00838 · Cited by 482
Role of the NLRP3 inflammasome in cancer
Moossavi, M., Parsamanesh, N., Bahrami, A., Atkin, S. L., & Sahebkar, A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0900-3 · Cited by 417
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
Musso, G., Cassader, M., & Gambino, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.3 · Cited by 412
REV-ERBα integrates colon clock with experimental colitis through regulation of NF-κB/NLRP3 axis
Wang, S., Lin, Y., Yuan, X., Li, F., Guo, L., & Wu, B. (2018) · Nature Communications · doi:10.1038/s41467-018-06568-5 · Cited by 352
Role of inflammatory response in liver diseases: Therapeutic strategies
Campo, J. A. D., Gallego, P., & Grande, L. (2018) · World Journal of Hepatology · doi:10.4254/wjh.v10.i1.1 · Cited by 348
Pyroptosis, metabolism, and tumor immune microenvironment
Du, T., Gao, J., Li, P., Wang, Y., Qi, Q., Liu, X., Li, J., Wang, C., & Du, L. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.492 · Cited by 324
Melatonin alleviates acute lung injury through inhibiting the NLRP3 inflammasome
Zhang, Y., Li, X., Grailer, J. J., Wang, N., Wang, M., Yao, J., Zhong, R., Gao, G. F., Ward, P. A., Tan, D., et al. (2016) · Journal of Pineal Research · doi:10.1111/jpi.12322 · Cited by 282
Myokines: The endocrine coupling of skeletal muscle and bone
(2020) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2019.07.010 · Cited by 272
Role of the NLRP3 inflammasome in autoimmune diseases
Li, Z., Guo, J., & Bi, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110542 · Cited by 261
Inflammasome Priming in Sterile Inflammatory Disease
Patel, M. N., Carroll, R. G., Galván-Peña, S., Mills, E. L., Olden, R., Triantafilou, M., Wolf, A. I., Bryant, C. E., Triantafilou, K., & Masters, S. L. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.12.007 · Cited by 241
Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells
WANG, Y., KONG, H., ZENG, X., LIU, W., WANG, Z., YAN, X., WANG, H., & XIE, W. (2016) · Oncology Reports · doi:10.3892/or.2016.4569 · Cited by 186
Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury
Leaf, I. A., Nakagawa, S., Johnson, B. G., Cha, J. J., Mittelsteadt, K., Guckian, K. M., Gomez, I. G., Altemeier, W. A., & Duffield, J. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87532 · Cited by 151
Zhu, W., Cao, F.-S., Feng, J., Chen, H.-W., Wan, J.-R., Lu, Q., & Wang, J. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2016.11.037 · Cited by 134
“The pro-caspase-1, in turn, proteolytically cleaves prointerleukin (IL)-1β and pro-IL-18 into their active forms, thus aggravating the inflammatory reaction (Ozaki et al., 2015).”
BackgroundZhao, N., Li, C.-C., Di, B., & Xu, L.-L. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102515 · Cited by 103
Metaflammation: Tissue-Specific Alterations of the NLRP3 Inflammasome Platform in Metabolic Syndrome
Mastrocola, R., Aragno, M., Alloatti, G., Collino, M., Penna, C., & Pagliaro, P. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170407123522 · Cited by 76
Mangiferin from Pueraria tuberosa reduces inflammation via inactivation of NLRP3 inflammasome
Bulugonda, R. K., kumar, K. A., Gangappa, D., Beeda, H., Philip, G. H., Muralidhara Rao, D., & Faisal, S. M. (2017) · Scientific Reports · doi:10.1038/srep42683 · Cited by 74
Kim, J., Kim, S.-J., Jeong, H.-R., Park, J.-H., Moon, M., & Hoe, H.-S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903309 · Cited by 23
Metadata
- Authors
- Doyle, S., Ozaki, E., & Campbell, M.
- Venue
- Journal of Inflammation Research
- Publisher
- Informa UK Limited
- Published
- 2015-01
- Volume
- 8
- Pages
- 15
- ISSN
- 1178-7031 (ISSN-L)
- OpenAlex
- W2090450186
- Cited by
- 380
- References
- 125
- FWCI
- 14.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.